When cells survive, transplanted donor organs are more viableTime seems to slow down when you’re waiting for a life-saving donor organ to become available. Then, when an organ is ready for transplant, you only have a very short window in which it is viable. With our research on AAGP®, we’re working to improve that window by extending the length of time an organ for transplant can survive and improving how well the new organ adapts to its new environment.
The impact of AAGP®
Each day, about 80 people receive transplants, according to Health Resources and Services Administration. Currently, organs used in transplants can only survive for around four hours. With our proprietary anti-aging glycopeptide, AAGP®, we hope to extend organ viability to 24 hours.
We’re researching two major ways AAGP® can help: regenerative medicine and whole organ support, starting with a focus on tissue and organ replacements associated with diabetes.
- Islet cells for Type 1 diabetes
- Blood stem cells for cancer
- Cartilage for arthritis
- Retinal grafts for blindness
- Heart, liver, pancreas, or kidney transplants
Whole organ support
At ProtoKinetix, we calculate the market value of AAGP® in how well it can take care of patients. We want to help medical treatments become more successful in improving lives and helping cells survive. But we know that as an investor, you also want to know how our biotechnology can help you.
The 2025 market forecast for organ transplants is $51 billion. Investing in the future of medicine will help you and tens of thousands of people who receive transplants every year. The potential of our anti-aging glycopeptide is endless, and we’ve only seen the tip of the iceberg.
Invest with us
We’re already making headlines with our groundbreaking research on the impact AAGP® could have on transplant support.